Axsome Therapeutics, Inc. Ratios

Ratios Dec2013 Dec2014 Dec2015 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
Gross Margin 89.61%90.37%91.37%
EBT Margin 1,455.67%2,185.01%1,415.96%-373.99%-88.06%-74.45%
EBIT Margin 1,355.67%2,085.01%1,315.96%-359.33%-85.67%-72.74%
EBITDA Margin 1,355.67%2,085.01%1,315.96%-359.33%-85.67%-72.74%
Operating Margin 1,355.67%2,085.01%1,315.96%-359.33%-85.67%-72.74%
Net Margin 1,455.67%2,185.01%1,415.96%-373.99%-88.41%-74.47%
FCF Margin 1,202.10%1,689.61%1,067.39%-234.25%-53.83%-33.36%
Efficiency
Inventory Average 9.73M15.43M
Assets Average 459.86M578.37M
Equity Average 150.27M124.00M
Invested Capital 0.08M0.71M5.32M204.56M370.98M237.01M
Asset Utilization Ratio 0.590.67
Leverage & Solvency
Interest Coverage Ratio -13.56-20.85-13.16
Debt to Equity 0.910.973.31
Debt Ratio 0.300.310.33
Equity Ratio 0.330.320.10
Times Interest Earned -13.56-20.85-13.16
Valuation
Enterprise Value 164.27M1,423.99M3,148.62M3,379.97M3,785.05M
Market Capitalization 164.27M1,423.99M3,349.46M3,766.16M4,100.40M
Return Ratios
Return on Sales 14.56%21.85%14.16%-3.74%-0.88%-0.74%
Return on Capital Employed -0.72%-0.81%
Return on Assets -0.52%-0.50%
Return on Equity -1.59%-2.32%